Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 6/20 | 0.60 |
| ▸ | JAK3 | P52333 | 15/20 | 0.55 |
| ▸ | JAK2 | O60674 | 14/20 | 0.55 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | GRK6 | P43250 | 1/20 | 0.49 |
| ▸ | MUSK | O15146 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | STAT5B | P51692 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3776169 | 0.85 | JAK3 (0.72) | NTRK1JAK3JAK2CDK2MUSK | |
| SCHEMBL3772448 | 0.82 | JAK3 (0.57) | NTRK1JAK3JAK2CDK2AURKA | |
| SCHEMBL3773338 | 0.78 | JAK3 (0.53) | NTRK1JAK3JAK2CDK2AURKA | |
| SCHEMBL3664305 | 0.78 | PLK4 (0.44) | NTRK1AURKAAURKB | |
| SCHEMBL3028266 | 0.76 | JAK3 (0.70) | NTRK1JAK3JAK2CDK2AURKA | |
| SCHEMBL13014406 | 0.75 | NTRK1 (1.00) | NTRK1JAK3JAK2 | |
| SCHEMBL3772159 | 0.73 | JAK3 (0.61) | NTRK1JAK3JAK2CDK2AURKA | |
| SCHEMBL3033142 | 0.73 | NTRK1 (0.78) | NTRK1JAK3JAK2CDK2AURKA | |
| SCHEMBL3774509 | 0.72 | JAK2 (0.52) | NTRK1JAK3JAK2CDK2MUSK | |
| SCHEMBL588686 | 0.72 | JAK3 (0.68) | NTRK1JAK3JAK2CDK2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011545-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2015-01-08 | — | — | US | disclosed |
| US-20140155394-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2014-06-05 | — | — | US | disclosed |
| US-8486966-B2 | 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer | ASTRAZENECA AB (SE) | 2013-07-16 | — | — | US | disclosed |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011545-A1 | Chemical Compounds - 759 | MCL1, BCL9, BCL9L | NTRK1 4667/4885JAK3 363/4885JAK2 15/4885 |
| US-20140155394-A1 | Chemical Compounds - 759 | MCL1, BCL9, BCL9L | NTRK1 4667/4885JAK3 363/4885JAK2 15/4885 |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | THPO, MPL, MCL1 | NTRK1 4038/4885JAK3 170/4885JAK2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.